
News|Articles|October 19, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
New therapies on the way to lower Lp(a), a cardiovascular risk factor
4
Music-based sleep aids show the strongest evidence for improving sleep
5




















































